Fiztasovimab

N/A

Report date: 2024/04/01 10:57:04

Base Information

Drug NameFiztasovimab
Drug Alias NameNPC-21
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionImmunomodulatorsEnvelope glycoprotein B, gB inhibitors
TargetsEnvelope glycoprotein B, gB
Therapy Area/IndicationsCytomegalovirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNobelpharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNobelpharma Co Ltd
Inactive CompaniesN/A
Active IndicationsCytomegalovirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A